Thijs Feuth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thijs Feuth has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Jarmo Oksi
4 shared publicationsAndy I. M. Hoepelman
University Medical Center Utrecht
3 shared publications- Joop E. Arends
Utrecht University
3 shared publications Peter D. Siersema
University Medical Center Utrecht
3 shared publications- Andy Im Hoepelman
Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications Debbie Van Baarle
University Medical Center Utrecht
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Wiley in Journal of Sleep Research
- p. e70419
Risk Factors for Motor Vehicle Accidents in Obstructive Sleep Apnoea Patients With Long‐Term Continuous Positive Airway Pressure Therapy
In this study, we aim to establish risk factors for sleepiness while driving, motor‐vehicle accidents and near miss incidents in obstructive sleep apnoea patients with long‐term continuous positive airway pressure (CPAP) therapy. We performed a cross‐sectional study on 1327 consecutive CPAP‐treated obstructive sleep apnoea (OSA) patients who were scheduled for a routine 5‐year follow‐up in 2019–2020 at Turku University Hospital. We obtained data of self‐reported sleepiness while driving, motor vehicle accidents and near‐miss events via questionnaires and classified patients accordingly in different groups. We then compared demographic parameters, CPAP adherence, blood gas samples and OSA‐related symptoms via standardised questionnaires and applied standard statistical tests. Sufficient data was available from 1018 (76.7%) of 1327 patients. Two hundred and seventeen patients (21.3%) reported sleepiness while driving, near‐miss situations or motor vehicle accidents while driving. These patients were younger (mean age 60 vs. 66 years), and scored higher on Epworth Sleepiness Scale (mean 6.7 vs. 4.3), Insomnia Severity Index (mean 3.1 vs. 1.9) and Depression Scale (mean 7.1 vs. 4.8) than other patients ( p < 0.001 on all scores). Sleepiness while driving was more likely in those with weight gain of more than 5 kg within 5 years (58.6% vs. 40.0%, p = 0.019). CPAP adherence was similar across the groups. Capillary blood gases did not correlate with poor CPAP adherence or sleepiness while driving. In conclusion, sleepiness while driving in OSA patients with long‐term CPAP therapy was associated with weight gain as well as depressive and insomnia symptoms.
- 6 August 2026
- Published by Wiley in Journal of Sleep Research
- p. e70419
Open AccessRisk Factors for Motor Vehicle Accidents in Obstructive Sleep Apnoea Patients With Long‐Term Continuous Positive Airway Pressure Therapy
In this study, we aim to establish risk factors for sleepiness while driving, motor‐vehicle accidents and near miss incidents in obstructive sleep apnoea patients with long‐term continuous positive airway pressure (CPAP) therapy. We performed a cross‐sectional study on 1327 consecutive CPAP‐treated obstructive sleep apnoea (OSA) patients who were scheduled for a routine 5‐year follow‐up in 2019–2020 at Turku University Hospital. We obtained data of self‐reported sleepiness while driving, motor vehicle accidents and near‐miss events via questionnaires and classified patients accordingly in different groups. We then compared demographic parameters, CPAP adherence, blood gas samples and OSA‐related symptoms via standardised questionnaires and applied standard statistical tests. Sufficient data was available from 1018 (76.7%) of 1327 patients. Two hundred and seventeen patients (21.3%) reported sleepiness while driving, near‐miss situations or motor vehicle accidents while driving. These patients were younger (mean age 60 vs. 66 years), and scored higher on Epworth Sleepiness Scale (mean 6.7 vs. 4.3), Insomnia Severity Index (mean 3.1 vs. 1.9) and Depression Scale (mean 7.1 vs. 4.8) than other patients ( p < 0.001 on all scores). Sleepiness while driving was more likely in those with weight gain of more than 5 kg within 5 years (58.6% vs. 40.0%, p = 0.019). CPAP adherence was similar across the groups. Capillary blood gases did not correlate with poor CPAP adherence or sleepiness while driving. In conclusion, sleepiness while driving in OSA patients with long‐term CPAP therapy was associated with weight gain as well as depressive and insomnia symptoms.
- Open Access
- 2 July 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (10) , 1224-1226
GWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways
Summary: Four of 67 loci were specific to antihistamine use; most overlapped inflammatory disease susceptibility. Genetic variation enriched in IL‐2 cytokine, JAK–STAT pathway genes shared by allergy and autoimmunity.
- 2 July 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (10) , 1224-1226
Open AccessGWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways
Summary: Four of 67 loci were specific to antihistamine use; most overlapped inflammatory disease susceptibility. Genetic variation enriched in IL‐2 cytokine, JAK–STAT pathway genes shared by allergy and autoimmunity.
- Open Access
- 18 March 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (6) , 1-9
Screening and treatment practices for tuberculosis infection in Nordic, Baltic and Central European countries and Ukraine in 2023
Purpose: Throughout Europe, tuberculosis (TB) remains a public health concern, particularly among high-risk groups. Identifying at-risk populations for tuberculosis infection (TBI) testing and treatment is one of the tools to control the TB epidemic. This study aims to assess policies and practices in tuberculosis infection management across 10 countries in the Nordic, Baltic and Central European region, collaborating through the Northern Dimension Partnership in Public Health and Social Well-being network (NDPHS), and Ukraine. Methods: National data on TB epidemiology, management and policies were collected through an online questionnaire, followed by structured interviews with country representatives. Data were verified and meaningful similarities and differences were identified through follow-up contacts and working group discussions. Results: Among NDPHS countries, TB incidence ranged from 3 to 22 per 100,000 population in 2023, with multidrug resistance in 4.1% (441/10855) of cases. In NDPHS countries, Ukrainians accounted for 46.4% (189/407) of multidrug-resistant cases. While all countries screen for TBI among immunosuppressed patients and TB contacts, approaches to refugee screening and preventive treatment vary, 5 of 11 countries lacked access to rifapentine. Most countries did not utilize levofloxacin in the preventive treatment of multidrug-resistant TBI. Two countries reported having a national registry for TBI. Conclusion: Significant variation exists in TBI management across countries. Optimizing screening and treatment strategies directed at populations at risk is crucial for TB control in low-incidence countries. Cross-border coordination could be improved through alignment with international guidelines and by establishing an international registry for TBI.
- 18 March 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (6) , 1-9
Open AccessScreening and treatment practices for tuberculosis infection in Nordic, Baltic and Central European countries and Ukraine in 2023
Purpose: Throughout Europe, tuberculosis (TB) remains a public health concern, particularly among high-risk groups. Identifying at-risk populations for tuberculosis infection (TBI) testing and treatment is one of the tools to control the TB epidemic. This study aims to assess policies and practices in tuberculosis infection management across 10 countries in the Nordic, Baltic and Central European region, collaborating through the Northern Dimension Partnership in Public Health and Social Well-being network (NDPHS), and Ukraine. Methods: National data on TB epidemiology, management and policies were collected through an online questionnaire, followed by structured interviews with country representatives. Data were verified and meaningful similarities and differences were identified through follow-up contacts and working group discussions. Results: Among NDPHS countries, TB incidence ranged from 3 to 22 per 100,000 population in 2023, with multidrug resistance in 4.1% (441/10855) of cases. In NDPHS countries, Ukrainians accounted for 46.4% (189/407) of multidrug-resistant cases. While all countries screen for TBI among immunosuppressed patients and TB contacts, approaches to refugee screening and preventive treatment vary, 5 of 11 countries lacked access to rifapentine. Most countries did not utilize levofloxacin in the preventive treatment of multidrug-resistant TBI. Two countries reported having a national registry for TBI. Conclusion: Significant variation exists in TBI management across countries. Optimizing screening and treatment strategies directed at populations at risk is crucial for TB control in low-incidence countries. Cross-border coordination could be improved through alignment with international guidelines and by establishing an international registry for TBI.
- Open Access
- 10 February 2026
- Published by Wiley
GWAS of Second-Generation Antihistamine Use: Locus Specificity and Highlighted Signaling Pathways
Background Second-generation H 1 -antagonists are widely used to treat multiple allergic and non-allergic chronic conditions. Aims We aimed to identify genetic loci, locus specificity, and enriched signaling pathways associated with long-term systemic second-generation antihistamine (sgAH) use in the context of underlying diseases. Materials and Methods In FinnGen, 38,645 individuals with ≥10 sgAH purchases from Finnish pharmacies were identified, while 201,334 individuals with no such purchases served as controls. Comprehensive drug purchase records and clinical diagnoses were retrieved from national registries. Genome-wide association analysis (GWAS) of sgAH use was conducted using Regenie (17 million genotyped and imputed variants). MAGMA was employed for gene and pathway-level enrichment analysis, and phenotypic specificity of associations was evaluated using MetABF. Results In GWAS for sgAH use, we identified 67 independent loci at genome wide significance (P-8 ). Four of identified loci (near DELEC1/TNFSF8, POU2AF1, RNY1P8/KLF5, and LINC00334/POFUT2 ) were specific for sgAH use. The remaining loci also demonstrated genome-wide significant associations with conditions such as asthma, chronic rhinitis, conjunctivitis, atopic eczema, sinusitis, and urticaria, all of which are indicative of sgAH use. Missense variants were observed in IL6RA , IL4RA , TESPA1 , C17orf58, and one lost-of-function mutation in FLG . The TESPA1 variant lies in a conserved region, suggesting potential structural impact. MAGMA analysis revealed significant associations with four gene sets, including IL-2 family cytokines (P=5.0×10 -9 ). Conclusions Most loci associated with sgAH use overlap with those implicated in the underlying, immune mediated diseases. Independent of diagnosis, IL-2 family cytokines signaling via the common γ-chain and the JAK–STAT pathway is significantly enriched among long-term sgAH users.
- 10 February 2026
- Published by Wiley
Open AccessGWAS of Second-Generation Antihistamine Use: Locus Specificity and Highlighted Signaling Pathways
Background Second-generation H 1 -antagonists are widely used to treat multiple allergic and non-allergic chronic conditions. Aims We aimed to identify genetic loci, locus specificity, and enriched signaling pathways associated with long-term systemic second-generation antihistamine (sgAH) use in the context of underlying diseases. Materials and Methods In FinnGen, 38,645 individuals with ≥10 sgAH purchases from Finnish pharmacies were identified, while 201,334 individuals with no such purchases served as controls. Comprehensive drug purchase records and clinical diagnoses were retrieved from national registries. Genome-wide association analysis (GWAS) of sgAH use was conducted using Regenie (17 million genotyped and imputed variants). MAGMA was employed for gene and pathway-level enrichment analysis, and phenotypic specificity of associations was evaluated using MetABF. Results In GWAS for sgAH use, we identified 67 independent loci at genome wide significance (P-8 ). Four of identified loci (near DELEC1/TNFSF8, POU2AF1, RNY1P8/KLF5, and LINC00334/POFUT2 ) were specific for sgAH use. The remaining loci also demonstrated genome-wide significant associations with conditions such as asthma, chronic rhinitis, conjunctivitis, atopic eczema, sinusitis, and urticaria, all of which are indicative of sgAH use. Missense variants were observed in IL6RA , IL4RA , TESPA1 , C17orf58, and one lost-of-function mutation in FLG . The TESPA1 variant lies in a conserved region, suggesting potential structural impact. MAGMA analysis revealed significant associations with four gene sets, including IL-2 family cytokines (P=5.0×10 -9 ). Conclusions Most loci associated with sgAH use overlap with those implicated in the underlying, immune mediated diseases. Independent of diagnosis, IL-2 family cytokines signaling via the common γ-chain and the JAK–STAT pathway is significantly enriched among long-term sgAH users.
- Top Cited PapersOpen Access
- 17 October 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (10) , e70046
Interactions between sleep, inflammation, immunity and infections: A narrative review
Background: Over the past decades, it has become increasingly evident that sleep disturbance contributes to inflammation‐mediated disease, including depression, mainly through activation of the innate immune system and to an increased risk of infections.Methods: A comprehensive literature search was performed in PubMed to identify relevant research findings in the field of immunity, inflammation and infections, with a focus on translational research findings from the past 5 years.Results: Physiological sleep is characterized by a dynamic interplay between the immune system and sleep architecture, marked by increased innate immunity and T helper 1 (Th1) ‐mediated inflammation in the early phase, transitioning to a T helper 2 (Th2) response dominating in late sleep. Chronic sleep disturbances are associated with enhanced inflammation and an elevated risk of infections, while other inflammatory diseases may also be affected. Conversely, inflammation in response to infection can also disrupt sleep patterns and architecture. This narrative review summarizes current data on the complex relationships between sleep, immunity, inflammation and infections, while highlighting translational aspects. The bidirectional nature of these interactions are addressed within specific conditions such as sleep apnea, HIV, and other infections. Furthermore, technical developments with the potential to accelerate our understanding of these interactions are identified, including advances in wearable devices, artificial intelligence, and omics technology. By integrating these tools, novel biomarkers and therapeutic targets for sleep‐related immune dysregulation may be identified.Conclusion: The review underscores the importance of understanding and addressing immune imbalance related to sleep disturbances to improve disease outcomes.
- 17 October 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (10) , e70046
Top Cited PapersOpen AccessInteractions between sleep, inflammation, immunity and infections: A narrative review
Background: Over the past decades, it has become increasingly evident that sleep disturbance contributes to inflammation‐mediated disease, including depression, mainly through activation of the innate immune system and to an increased risk of infections.Methods: A comprehensive literature search was performed in PubMed to identify relevant research findings in the field of immunity, inflammation and infections, with a focus on translational research findings from the past 5 years.Results: Physiological sleep is characterized by a dynamic interplay between the immune system and sleep architecture, marked by increased innate immunity and T helper 1 (Th1) ‐mediated inflammation in the early phase, transitioning to a T helper 2 (Th2) response dominating in late sleep. Chronic sleep disturbances are associated with enhanced inflammation and an elevated risk of infections, while other inflammatory diseases may also be affected. Conversely, inflammation in response to infection can also disrupt sleep patterns and architecture. This narrative review summarizes current data on the complex relationships between sleep, immunity, inflammation and infections, while highlighting translational aspects. The bidirectional nature of these interactions are addressed within specific conditions such as sleep apnea, HIV, and other infections. Furthermore, technical developments with the potential to accelerate our understanding of these interactions are identified, including advances in wearable devices, artificial intelligence, and omics technology. By integrating these tools, novel biomarkers and therapeutic targets for sleep‐related immune dysregulation may be identified.Conclusion: The review underscores the importance of understanding and addressing immune imbalance related to sleep disturbances to improve disease outcomes.
- Open Access
- 3 July 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (3) , 106217
Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial
- 3 July 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (3) , 106217
Open AccessShort- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial
- Open Access
- 25 June 2024
- Published by Elsevier in CMI Communications
- Vol. 1 (2)
Approach to prolonged viral pneumonia in immunocompromised patients with COVID-19
- 25 June 2024
- Published by Elsevier in CMI Communications
- Vol. 1 (2)
Open AccessApproach to prolonged viral pneumonia in immunocompromised patients with COVID-19
- Open Access
- 15 February 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (4) , 723-734
Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy
Purpose: In clinical practice, we observed an apparent overrepresentation of COVID-19 patients on anti-CD20 monoclonal antibody therapy. The aim of this study was to characterize the clinical picture of COVID-19 in these patients. Methods: All adult patients from Turku University Hospital, Turku, Finland, with COVID-19 diagnosis and/or positive SARS-CoV-2 PCR test result up to March 2023, and with anti-CD20 therapy within 12 months before COVID-19 were included. Data was retrospectively obtained from electronic patient records. Results: Ninety-eight patients were identified. 44/93 patients (47.3%) were hospitalized due to COVID-19. Patients with demyelinating disorder (n = 20) were youngest (median age 36.5 years, interquartile range 33–45 years), had less comorbidities, and were least likely to be hospitalized (2/20; 10.0%) or die (n = 0). COVID-19 mortality was 13.3% in the whole group, with age and male sex as independent risk factors. Persistent symptoms were documented in 33/94 patients (35.1%) alive by day 30, in 21/89 patients (23.6%) after 60 days, and in 15/85 after 90 days (17.6%), mostly in patients with haematological malignancy or connective tissue disease. Prolonged symptoms after 60 days predisposed to persistent radiological findings (odds ratio 64.0; 95% confidence interval 6.3–711; p < 0.0001) and persistently positive PCR (odds ratio 45.5, 95% confidence interval 4.0–535; p < 0.0001). Several patients displayed rapid response to late antiviral therapy. Conclusion: Anti-CD20 monoclonal antibody therapy is associated with high COVID-19 mortality and with a phenotype consistent with prolonged viral pneumonia. Our study provides rationale for retesting of immunocompromised patients with prolonged COVID-19 symptoms and considering antiviral therapy.
- 15 February 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (4) , 723-734
Open AccessProlonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy
Purpose: In clinical practice, we observed an apparent overrepresentation of COVID-19 patients on anti-CD20 monoclonal antibody therapy. The aim of this study was to characterize the clinical picture of COVID-19 in these patients. Methods: All adult patients from Turku University Hospital, Turku, Finland, with COVID-19 diagnosis and/or positive SARS-CoV-2 PCR test result up to March 2023, and with anti-CD20 therapy within 12 months before COVID-19 were included. Data was retrospectively obtained from electronic patient records. Results: Ninety-eight patients were identified. 44/93 patients (47.3%) were hospitalized due to COVID-19. Patients with demyelinating disorder (n = 20) were youngest (median age 36.5 years, interquartile range 33–45 years), had less comorbidities, and were least likely to be hospitalized (2/20; 10.0%) or die (n = 0). COVID-19 mortality was 13.3% in the whole group, with age and male sex as independent risk factors. Persistent symptoms were documented in 33/94 patients (35.1%) alive by day 30, in 21/89 patients (23.6%) after 60 days, and in 15/85 after 90 days (17.6%), mostly in patients with haematological malignancy or connective tissue disease. Prolonged symptoms after 60 days predisposed to persistent radiological findings (odds ratio 64.0; 95% confidence interval 6.3–711; p < 0.0001) and persistently positive PCR (odds ratio 45.5, 95% confidence interval 4.0–535; p < 0.0001). Several patients displayed rapid response to late antiviral therapy. Conclusion: Anti-CD20 monoclonal antibody therapy is associated with high COVID-19 mortality and with a phenotype consistent with prolonged viral pneumonia. Our study provides rationale for retesting of immunocompromised patients with prolonged COVID-19 symptoms and considering antiviral therapy.
- Open Access
- 15 November 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-9
Rapid implementation of home oxygen treatment and remote monitoring for COVID-19 patients at the verge of the Omicron wave in Turku, Finland
Background: In Turku, Finland, we introduced a home oxygen treatment and app-based monitoring program for hospitalized COVID-19 patients to facilitate an early discharge during the Omicron wave. In this case series we explore the clinical parameters of patients enrolled in the program and evaluate the cost–benefit and safety issues of the program. Methods: Hospitalized COVID-19 patients with marked hypoxemia but otherwise in stable condition were screened from Turku City Hospital and Turku University Hospital by treating doctors for eligibility in the program. Peripheral oxygen saturation of > 92% and breathing frequency < 30/min in rest with oxygen supplementation were among the criteria. All patients actively participating in the program between 10th of January 2022 and 30th of September 2022 were included in this case series. Clinical data of hospitalization and monitoring were analysed, and cost–benefit evaluation was based on the number of saved hospitalization days. Results: Nineteen COVID-19 patients were included in this case series and recruited from three different hospital departments in the Turku city region, South-West Finland. All patients were male, the median age was 59 years and the median duration of hospitalization before enrolment in the program was 6 days (range 3—20 days). The median duration of home oxygen treatment was 13 days (range 3—72 days) and the median duration of home monitoring was 18 days (range 7—41 days). A total of 210,5 hospital days were prevented, resulting in savings of €144,490 of healthcare expenditure (on average 9 days and €7,605 per patient). No major safety issues were reported during the program. Conclusions: In our case series, home oxygen treatment combined with home monitoring was safe and economically beneficial. Application based monitoring could be considered in other post-acute pulmonary conditions to reduce hospitalization and healthcare costs.
- 15 November 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-9
Open AccessRapid implementation of home oxygen treatment and remote monitoring for COVID-19 patients at the verge of the Omicron wave in Turku, Finland
Background: In Turku, Finland, we introduced a home oxygen treatment and app-based monitoring program for hospitalized COVID-19 patients to facilitate an early discharge during the Omicron wave. In this case series we explore the clinical parameters of patients enrolled in the program and evaluate the cost–benefit and safety issues of the program. Methods: Hospitalized COVID-19 patients with marked hypoxemia but otherwise in stable condition were screened from Turku City Hospital and Turku University Hospital by treating doctors for eligibility in the program. Peripheral oxygen saturation of > 92% and breathing frequency < 30/min in rest with oxygen supplementation were among the criteria. All patients actively participating in the program between 10th of January 2022 and 30th of September 2022 were included in this case series. Clinical data of hospitalization and monitoring were analysed, and cost–benefit evaluation was based on the number of saved hospitalization days. Results: Nineteen COVID-19 patients were included in this case series and recruited from three different hospital departments in the Turku city region, South-West Finland. All patients were male, the median age was 59 years and the median duration of hospitalization before enrolment in the program was 6 days (range 3—20 days). The median duration of home oxygen treatment was 13 days (range 3—72 days) and the median duration of home monitoring was 18 days (range 7—41 days). A total of 210,5 hospital days were prevented, resulting in savings of €144,490 of healthcare expenditure (on average 9 days and €7,605 per patient). No major safety issues were reported during the program. Conclusions: In our case series, home oxygen treatment combined with home monitoring was safe and economically beneficial. Application based monitoring could be considered in other post-acute pulmonary conditions to reduce hospitalization and healthcare costs.
- Open Access
- 24 August 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9 (9) , e1527
Tuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country
Background.: World Health Organization recommends tuberculosis (TB) preventive treatment for risk groups such as patients preparing for organ transplantation. Pretransplant screening or treatment of latent TB infection has not been routine practice in Finland. Methods.: In this nationwide registry study, we assessed the risk of TB among kidney transplant recipients compared to the general population. TB cases were identified by data linkage of the national infectious disease and the national transplant registries between 1995 and 2019. Standardized incidence ratios were calculated with adjustment for age, sex, and annual TB dynamics. Results.: A total of 4101 kidney transplants in 3900 recipients with a follow-up of 37 652 patient-years were included. Eighteen TB cases were detected. Patients diagnosed with TB were older (median age 64 y, interquartile range 56–66) at transplantation than those without TB (median 51 y, interquartile range 41–60, P < 0.001). The standardized incidence ratio of TB was 6.9 among kidney transplant recipients compared to general population during the whole study period 1995–2019 but decreased from 12.5 in 1995–2007 to 3.2 in 2008–2019. The standardized incidence ratio was 44.2 during the first year after transplantation. Significant differences in 5-y graft losses were not detected between TB patients and those without TB. Conclusions.: The standardized incidence ratio of TB in kidney transplant recipients has decreased over the years, but these patients remain at risk of TB, especially during the first posttransplant year. Cost-benefit analysis is required to address feasibility of latent TB infection screening among transplant candidates in countries with low incidence of TB.
- 24 August 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9 (9) , e1527
Open AccessTuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country
Background.: World Health Organization recommends tuberculosis (TB) preventive treatment for risk groups such as patients preparing for organ transplantation. Pretransplant screening or treatment of latent TB infection has not been routine practice in Finland. Methods.: In this nationwide registry study, we assessed the risk of TB among kidney transplant recipients compared to the general population. TB cases were identified by data linkage of the national infectious disease and the national transplant registries between 1995 and 2019. Standardized incidence ratios were calculated with adjustment for age, sex, and annual TB dynamics. Results.: A total of 4101 kidney transplants in 3900 recipients with a follow-up of 37 652 patient-years were included. Eighteen TB cases were detected. Patients diagnosed with TB were older (median age 64 y, interquartile range 56–66) at transplantation than those without TB (median 51 y, interquartile range 41–60, P < 0.001). The standardized incidence ratio of TB was 6.9 among kidney transplant recipients compared to general population during the whole study period 1995–2019 but decreased from 12.5 in 1995–2007 to 3.2 in 2008–2019. The standardized incidence ratio was 44.2 during the first year after transplantation. Significant differences in 5-y graft losses were not detected between TB patients and those without TB. Conclusions.: The standardized incidence ratio of TB in kidney transplant recipients has decreased over the years, but these patients remain at risk of TB, especially during the first posttransplant year. Cost-benefit analysis is required to address feasibility of latent TB infection screening among transplant candidates in countries with low incidence of TB.